The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
HOME > COMMENTARY
COMMENTARY
- Policymakers Face Balancing Act over Opdivo Re-Pricing
October 17, 2016
- Can Wholesalers Bear Distribution Costs amid 90% Discount on Generics?
October 11, 2016
- Can Mid-sized Makers Break Away from Long-Listed Product Model?
August 19, 2016
- MHLW’s Feat to Link Drug Review and Reimbursement Policies Put to Test with “Expensive Drugs”
June 28, 2016
- 7 Drugs Picked for Cost-Effective Assessments, but Now How Will They Be Re-Priced Exactly?
May 27, 2016
- Data Corroborate Harshness of Z2 Rule, Only Handful to Escape 2nd Consecutive Application
March 31, 2016
- Global Pharmas Casting Colder Eyes on Japan Market; PhRMA, EFPIA to Up Lobbying Efforts with Govt, Ruling Parties
March 11, 2016
- Companies Can “Veto” Humanitarian Trials for Legitimate Reasons; Cooperation Is Essential, but Access Scheme Shouldn’t Stymie Main Development
February 23, 2016
- It’s Time to Squarely Discuss Proposed Penalty through Drug Price Cuts
February 3, 2016
- Generic Industry’s Tactic to Thwart 50% Pricing Rule Draws Mixed Reviews
January 18, 2016
- Is 7.8% Drug Cost Cut Justifiable? Make “Huge Seller” Re-Pricing a Starter to Discuss This
January 12, 2016
- High Hopes for New Osteoporosis Drugs, but “Treatment Gap” Needs to Be Addressed
November 27, 2015
- Sakigake Designation System to Link Regulatory and Drug Pricing Systems; Could Result in Tougher Scrutiny for Designated Products
November 6, 2015
- Data from Humanitarian Trials to Be Used in Product Reviews; Effective Use of Safety-Related Information Will Be Key
October 13, 2015
- Japan, US, EU Regulators Trod Different Paths to Iressa Approval; Japan’s Capabilities to Be Tested with Sakigake System
September 24, 2015
- How Will Industry Counter Proposed Re-Pricing of “Huge Seller” Drugs?
August 18, 2015
- Leaner Sales Forces? Lower Profits? Drug Makers Face Tough Decision in 80% Generic Era
August 14, 2015
- PMDA Poised to Tap Big Data to Refine Reviews, Safety Steps; Dedicated Center Eyed in 2018
August 12, 2015
- Wholesalers Face Pressing Need to Retool Biz Strategy as Generics Gain Ground
July 21, 2015
- Viable Third-Party Review System Required for Drug Makers’ Advertisements
July 7, 2015
ページ
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…